A biotech-focused article on a federally backed human-cell and AI drug-discovery approach for Duchenne cardiomyopathy, highlighting its potential to replace animal models and accelerate orphan-disease programs.
Key Takeaways
- By the numbers, the translational gap is expensive
- Roughly nine in ten drug candidates that succeed in animal models still fail once they reach human trials
- Generative AI has become a fixture of drug-discovery marketing